Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease in children. As one the first genetic defects, the underlying mutation in the DMD gene was described more than 25 years ago. At that time the disease was in the epicenter of genetic diagnostics. Now pioneering work is being done on new, gene-based therapies -somatic gene therapy, termination codon read-through and exon skipping are already investigated in clinical trials.
The improvement and wider application of these methods is hampered by the existing animal models which do not sufficiently reflect the human disease. This is a common problem for most rare diseases and an important barrier in the translation from experimental reserach to clinical application. This is where the paper from Klymiuk et al. comes into play. The team from the research association MD-Net generated DMD-deficient pigs whose clinical presentation is much closer to that of DMD patients. In addition, the type of mutation generated is more comparable with the relevant human DMD mutations. This is important because gene-based therapies crucially depend on the defect that needs to be corrected. Regarding disease presentation, the animals showed accelerated development of the disease and virtually mirror the human pathogenesis in fast motion. Early and late changes occurring in the progression of the disease were differentiated on the basis of transcriptome data.
Overall, the presented animal model offers the possibility to systematically improve new gene-based therapies for DMD. There is hope that this knowledge will beneficial in the development of novel therapies for other rare diseases as well. 
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